Table 3.

BPDE-induced 9p21 deletions and bladder cancer risk

Variablesn (%)
Adjusted OR (95% CI)*
CasesControls
Overall
    Low sensitivity34 (16.7)98 (49.5)
    High sensitivity169 (83.3)100 (50.5)5.28 (3.26-8.59)
Age
Dichotomize
    <62
        Low sensitivity13 (17.3)36 (48.0)
        High sensitivity62 (82.7)39 (52.0)4.93 (2.23-10.90)
    ≥62
        Low sensitivity21 (16.4)62 (50.4)
        High sensitivity107 (83.6)61 (49.6)5.49 (2.94-10.27)
Tertile analysis
    ≤60
        Low sensitivity11 (16.2)35 (51.5)
        High sensitivity57 (83.8)33 (48.5)6.36 (2.71-14.91)
    61-69
        Low sensitivity16 (23.5)35 (46.7)
        High sensitivity52 (76.5)40 (53.3)2.89 (1.34-6.24)
    ≥70
        Low sensitivity7 (10.4)28 (50.9)
        High sensitivity60 (89.6)27 (49.1)11.24 (3.78-33.38)
Gender
    Male
        Low sensitivity27 (17.3)75 (49.7)
        High sensitivity129 (82.7)76 (50.3)5.37 (3.07-9.37)
    Female
        Low sensitivity7 (14.9)23 (48.9)
        High sensitivity40 (85.1)24 (51.1)5.56 (2.03-15.25)
Smoking status
    Never
        Low sensitivity5 (8.9)31 (39.7)
        High sensitivity51 (91.1)47 (60.3)7.13 (2.52-20.20)
    Former
        Low sensitivity19 (20.0)56 (56.6)
        High sensitivity76 (80.0)43 (43.4)5.19 (2.72-9.90)
    Current
        Low sensitivity10 (19.2)11 (52.4)
        High sensitivity42 (80.8)10 (47.6)4.20 (1.28-13.84)
  • * Adjusted by age, gender, ethnicity, and smoking status.

  • Dichotomized at the median value of 9p21aberrations in the controls.